By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Cynapsus Therapeutics 

828 Richmond Street West

Toronto  Ontario  M6J 1C9  Canada
Phone: 416-703-2449 Fax: 416-703-8752


SEARCH JOBS

Cynapsus is a specialty pharmaceutical company developing a convenient and easy to use sublingual (oral) thin film strip for the acute rescue of “off” motor symptoms of Parkinson’s disease. Cynapsus’ drug candidate, APL-130277, is an easy-to-administer, fast-acting reformulation of apomorphine, which is the only approved drug (in the United States, Europe, Japan and other countries) to rescue patients from “off” episodes. Cynapsus is focused on maximizing the value of APL-130277 by completing pivotal studies in advance of a New Drug Application (“NDA”) expected to be submitted in 2016. The company is located in Toronto, ON.


Key Statistics


Email: info@cynapsus.ca
Ownership: Public

Web Site: Cynapsus Therapeutics
Employees: 10
Symbol: CYNAF
 



Industry
Pharmaceutical






Company News
Cynapsus Therapeutics (CYNAF) Reports 2014 Annual Results 3/18/2015 10:08:31 AM
Cynapsus Therapeutics (CYNAF) To Host Analyst And Investor Breakfast In New York City On March 18 3/16/2015 10:49:44 AM
Cynapsus Therapeutics (CYNAF) Appoints Tamar Howson To Board Of Directors 3/13/2015 10:04:21 AM
Cynapsus Therapeutics (CYNAF) Provides Clinical And Regulatory Update For APL-130277 For The Acute Rescue Of OFF Motor Symptoms Of Parkinson’s Disease 3/12/2015 10:28:44 AM
Cynapsus Therapeutics (CYNAF) To Present At The D2 2015 - Noble Financial Capital Markets' Eleventh Annual Investor / Equity Conference 1/16/2015 10:16:44 AM
Cynapsus Therapeutics (CYNAF) Announces Uplisting To The Toronto Stock Exchange’s Senior Equity Market 11/26/2014 8:42:45 AM
Cynapsus Therapeutics (CYNAF) Announces Positive Top-Line Results From CTH-105 Phase 2 Study Of APL-130277 For The Treatment Of OFF Episodes In Patients With Parkinson's Disease 11/19/2014 6:01:01 AM
Cynapsus Therapeutics (CYNAF) Announces Hiring Of New Chief Scientific Officer And EVP, CMC 10/7/2014 3:24:06 PM
Cynapsus Therapeutics Awarded Second Grant From The Michael J. Fox Foundation For Parkinson's Research 7/8/2014 10:24:34 AM
Cynapsus Therapeutics Announces No Buccal Mucosal Irritation In FDA Registration Study Of APL-130277 For Parkinson’s Disease 5/14/2014 11:55:20 AM
12
//-->